Table 1.

Baseline Characteristics	N=26
Median age, years (range)	74 (53–87)
Median disease duration, months (range)	18.1 (1.4–221.4)
Disease subtype
PMF	17 (65.4%)
PPV-MF	8 (30.8%)
PET-MF	1 (3.8%)
Lille Score
0	11 (42.3%)
1	11 (42.3%)
2	4 (15.4%)
DIPSS
Intermediate-1 risk	4 (15.4%)
Intermediate-2 risk	8 (30.8%)
High risk	14 (53.8%)
Karyotype
Favorable	14 (53.8%)
Unfavorable	7 (26.9%)
Not available	5 (19.2%)
Median spleen size, cm
0	3 (11.5%)
1–10	3(11.5%)
11–20	13(50.0%)
>20	7(26.9%)
Median number of prior MF treatments
0	3(11.5%)
1	12(46.2%)
2	7(26.9%)
3	2(7.7%)
4	1(3.8%)
5	1(3.8%)
Prior JAK2 inhibitors	2 (7.7%)
JAK2V617Fallele burden(%)
Missing	11
<50%	2(11.87%)
>=50%	15(88.2%)